Effects of the chemotherapeutic agents for non-hodgkin lymphoma, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), on the male rat reproductive system and progeny outcome

被引:34
|
作者
Vaisheva, Farida
Delbes, Geraldine
Hales, Barbara F.
Robaire, Bernard
机构
[1] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada
[2] McGill Univ, Dept Obstet & Gynecol, Montreal, PQ, Canada
来源
JOURNAL OF ANDROLOGY | 2007年 / 28卷 / 04期
关键词
anticancer drugs; spermatogenesis; male germ cell; apoptosis; adverse effects; developmental toxicity;
D O I
10.2164/jandrol.106.002428
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Chemotherapy of non-Hodgkin lymphoma (NHL) with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) is associated with significant gonadal damage. Our goal was to determine the impact of CHOP chemotherapy on the male reproductive system, fertility, and progeny outcome in the rat model. Adult male Sprague-Dawley rats received saline or CHOP, 4 cycles of 3 weeks each, at doses analogous to 1/3 x, 2/3 x, or 1 x the human dose; males were mated to evaluate effects on progeny outcome. Reproductive organ weights were significantly decreased in the 1 x CHOP-exposed group. The spermatozoal contents of the testes and epididymides were decreased in 1 X CHOP-treated males; the 1/3 x and 2/3 x doses also affected testicular sperm contents. Seminiferous tubule diameters were decreased by 20% in 1 X CHOP-treated males. Damage ranged from the presence of small vacuoles in the epithelium to tubules deprived of spermato- cytes and spermatids and was accompanied by an increased incidence of germ cell apoptosis. The acridine orange assay revealed a significant increase in sperm with abnormal DNA integrity profiles in the 1 X CHOP group. Despite effects on germ cell number and quality, CHOP-exposed rats remained fertile. However, a 50% decrease in live fetuses was observed in litters sired by 1 x CHOP-treated males due to a significant increase in both pre-implantation and postimplantation losses; postimplantation loss was also elevated among litters sired by 2/3 X CHOP-treated males. Thus, CHOP treatment affected both the quantity and quality of male germ cells; conceptal loss is a sensitive measure of the integrity of the male genome.
引用
收藏
页码:578 / 587
页数:10
相关论文
共 50 条
  • [31] A phase II trial of pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non-Hodgkin's lymphoma
    Tulpule, A
    Khan, AU
    Mohrbacher, AF
    Espina, BM
    Buchanan, L
    Berman, N
    Gorospe, G
    Boswell, WD
    Nathwani, BN
    Levine, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 604S - 604S
  • [32] Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma
    Visani, G
    Guiducci, B
    D'Adamo, F
    Mele, A
    Nicolini, G
    Leopardi, G
    Sparaventi, G
    Barulli, S
    Malerba, L
    Isidori, A
    Malagola, M
    Piccaluga, PP
    LEUKEMIA & LYMPHOMA, 2005, 46 (03) : 477 - 479
  • [33] Reply to Magnetic Resonance Imaging-Based Diagnosis of Progressive Multifocal Leukoencephalopathy in a Patient With Non-Hodgkin Lymphoma After Therapy With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab
    Bennett, Charles L.
    Newsome, Scott D.
    Sartor, Oliver
    Carson, Kenneth R.
    CANCER, 2014, 120 (24) : 4006 - 4007
  • [34] A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515
    Stopeck, Alison T.
    Unger, Joseph M.
    Rimsza, Lisa M.
    LeBlanc, Michael
    Farnsworth, Brent
    Iannone, Maria
    Glenn, Martha J.
    Fisher, Richard I.
    Miller, Thomas P.
    BLOOD, 2012, 120 (06) : 1210 - 1217
  • [35] PHASE 1B STUDY COMBINING IBRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (R-CHOP) IN PATIENTS WITH CD20-POSITIVE B-CELL NON-HODGKIN LYMPHOMA (NHL)
    Younes, A.
    Flinn, I.
    Berdeja, J.
    Friedberg, J.
    Alberti, S.
    Thieblemont, C.
    Morschhauser, F.
    Hellemans, P.
    Hall, B.
    Smit, J.
    Skee, D.
    de Vries, R.
    Todorovic, M.
    Khan, I.
    Fourneau, N.
    Oki, Y.
    HAEMATOLOGICA, 2013, 98 : 356 - 356
  • [36] An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study
    Flinn, Ian W.
    Van der Jagt, Richard H.
    Kahl, Brad S.
    Wood, Peter
    Hawkins, Tim E.
    MacDonald, David
    Hertzberg, Mark
    Kwan, Yiu-Lam
    Simpson, David
    Craig, Michael
    Kolibaba, Kathryn
    Issa, Samar
    Munteanu, Mihaela C.
    Clementi, Regina
    Chen, Ling
    Burke, John M.
    BLOOD, 2012, 120 (21)
  • [37] Prediction model of male reproductive function damage caused by CHOP chemotherapy regimen for non-Hodgkin's lymphoma
    Zhang, Jiabao.
    Zhang, Aili
    Liu, Jiaxin
    Xiao, Xu
    Huang, Yun
    Zhou, Wei
    Chen, Shenghui
    Yu, Ping
    Xie, Yifeng
    Wang, Sili
    Chen, Zhan
    Zhang, Jianbao
    BMC CANCER, 2024, 24 (01)
  • [38] MITOXANTRONE, ETOPOSIDE AND BLEOMYCIN (MEB) CHEMOTHERAPY IN NON-HODGKINS-LYMPHOMA PATIENTS NON-ELEGIBLE FOR STANDARD CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (CHOP) COMBINATION
    TAGLIAFERRI, P
    MATANO, E
    REA, A
    FAMIANI, M
    CIARDIELLO, F
    TORTORA, G
    MONTESARCHIO, V
    MORABITO, A
    CARAGLIA, M
    DELAURENTIIS, M
    DEPLACIDO, S
    PALMIERI, G
    BIANCO, AR
    ONCOLOGY REPORTS, 1995, 2 (03) : 365 - 368
  • [39] Single institution retrospective study of infusional etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, (EPOCH) plus /- rituximab (R) as first line therapy for aggressive non-Hodgkin lymphoma.
    Lamar, Zanetta S.
    Fitzgerald, Nora
    Palmer, Jodi Michelle
    Gruber, Lindsey
    RaetskayaSolntseva, Olga
    Kennedy, LeAnne
    Vaidya, Rakhee
    Zamkoff, Kenneth Warren
    Hurd, David Duane
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Obinutuzumab (GA101) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or bendamustine for the first-line treatment of follicular non-Hodgkin lymphoma: final results from the maintenance phase of the phase Ib GAUDI study
    Dyer, M. J. S.
    Grigg, A.
    Diaz, M. Gonzalez
    Dreyling, M.
    Rule, S.
    Lei, G.
    Wassner-Fritsch, E.
    Knapp, A.
    Marlton, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 53 - 53